Leerink Swann Initiates Carbylan Therapeutics With Outperform

Analysts at Leerink Swann initiated coverage on

with a Outperform rating. The target price for Carbylan Therapeutics is set to $16. Carbylan Therapeutics' shares rose 9.04 percent to $5.91 in pre-market trading.